Laquinimod

Laquinimod

Chembox new
ImageFile=Laquinimod.svg
ImageSize=200
IUPACName=5-chloro-"N"-ethyl-4-hydroxy-1-methyl-2-oxo-
"N"-phenyl-1,2-dihydroquinoline-3-carboxamide
OtherNames=
Section1= Chembox Identifiers
CASNo=248282-07-7
PubChem=216469
SMILES=CCN(c1ccccc1)C(=O)C3=C(/O)c2c(Cl)cccc2N(C)C/3=O

Section2= Chembox Properties
Formula=C19H17ClN2O3
MolarMass=356.803 g/mol
Appearance=
Density=
MeltingPt=
BoilingPt=
Solubility=

Section3= Chembox Hazards
MainHazards=
FlashPt=
Autoignition=

Laquinimod is an experimental immunomodulator developed by Active Biotech and Teva. It is currently investigated as an oral treatment of multiple sclerosis (MS).

Laquimod is the successor of Active Biotech's failed experimental immunomodulator linomide. [cite journal |author=Tan IL, Lycklama à Nijeholt GJ, Polman CH et al |title=Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials |journal=Mult Scler |volume=6 |issue=2 |pages=99–104 |year=2000 |month=April |pmid=10773855]

The compound has been investigated in two Phase II trials using successive magnetic resonance scans (MRI). Laquinimod seems to be able to reduce the MS disease activity on MRI.cite journal |author=Comi G, Pulizzi A, Rovaris M, "et al" |title=Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study |journal=Lancet |volume=371 |issue=9630 |pages=2085–92 |year=2008 |month=June |pmid=18572078 |doi=10.1016/S0140-6736(08)60918-6] cite journal |author=Polman C, Barkhof F, Sandberg-Wollheim M et al |title=Treatment with laquinimod reduces development of active MRI lesions in relapsing MS |journal=Neurology |volume=64 |issue=6 |pages=987–91 |year=2005 |month=March |pmid=15781813 |doi=10.1212/01.WNL.0000154520.48391.69] However, the response to a given dose was discrepant between both studies. [cite journal |author=Keegan BM, Weinshenker BG |title=Laquinimod, a new oral drug for multiple sclerosis |journal=Lancet |volume=371 |issue=9630 |pages=2059–60 |year=2008 |month=June |pmid=18572062 |doi=10.1016/S0140-6736(08)60894-6]

The Phase III activities have been starting in 2008

External Links

* [http://clinicaltrials.gov/search/intervention=laquinimod Entries in NIH Study Registry]

References


Wikimedia Foundation. 2010.

Игры ⚽ Поможем сделать НИР

Look at other dictionaries:

  • Therapies under investigation for multiple sclerosis — Scientists continue their efforts to create new and better therapies for multiple sclerosis. There are a number of treatments under investigation that may improve function, curtail attacks, or limit the progression of the underlying disease. Many …   Wikipedia

  • Sclerose en plaques — Sclérose en plaques  Ne doit pas être confondu avec Sclérose. Pour les articles homonymes, voir Plaque et SEP. La sclérose en plaques (SEP) est une maladie neurologique auto immune chronique du système nerveux centra …   Wikipédia en Français

  • Sclérose en plaque — Sclérose en plaques  Ne doit pas être confondu avec Sclérose. Pour les articles homonymes, voir Plaque et SEP. La sclérose en plaques (SEP) est une maladie neurologique auto immune chronique du système nerveux centra …   Wikipédia en Français

  • Sclérose en plaques —  Ne doit pas être confondu avec Sclérose. Pour les articles homonymes, voir Plaque et SEP. Sclérose en plaques Classification et ressources externes …   Wikipédia en Français

  • Treatment of multiple sclerosis — Several therapies for multiple sclerosis (MS) exist, although there is no known cure. Multiple sclerosis is a chronic inflammatory demyelinating disease that affects the central nervous system (CNS). The most common initial course of the disease… …   Wikipedia

  • Multiple sclerosis — Classification and external resources Demyelination by MS. The CD68 colored tissue shows several macrophages in the area of the lesion. Original scale 1:100 ICD …   Wikipedia

  • Fingolimod — Drugbox IUPAC name = 2 amino 2 [2 (4 octylphenyl)ethyl] propane 1,3 diol CAS number = 162359 55 9 CAS supplemental = ATC prefix = ATC suffix = ATC supplemental = PubChem = 107969 DrugBank = chemical formula = C=19 | H=33 | N=1 | O=2 molecular… …   Wikipedia

  • Teva Pharmaceutical Industries — Ltd. Type Public (NASDAQ: TEVA),(TASE:  …   Wikipedia

  • Liste von Multiple-Sklerose-Wirkstoffen in der Erprobung — Für die immunmodulierende Langzeittherapie der Multiplen Sklerose sind derzeit acht Medikamente im deutschen Sprachraum zugelassen: drei Beta Interferone, Glatirameracetat, Mitoxantron, Azathioprin, Natalizumab und Fingolimod. Darüber hinaus gibt …   Deutsch Wikipedia

  • Teva — 255px Tipo Compañía Pública (NASDAQ: TEVA) Fundación 1901 Sede …   Wikipedia Español

Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”